These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25315815)

  • 1. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation.
    Martino M; Lanza F; Demirer T; Moscato T; Secondino S; Pedrazzoli P;
    Expert Opin Biol Ther; 2015 Feb; 15(2):195-211. PubMed ID: 25315815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary.
    Musio F
    Expert Rev Hematol; 2020 Nov; 13(11):1175-1188. PubMed ID: 33028115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period.
    Tran DH; Wong GT; Chee YE; Irwin MG
    Expert Opin Biol Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24219367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
    Gebara SN; Moubayed H
    J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
    Mundle SD
    Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia treatment of lymphoproliferative malignancies with erypoiesis: an overview of state of the art.
    Cacic DL; Hervig T; Seghatchian J
    Transfus Apher Sci; 2013 Apr; 48(2):277-81. PubMed ID: 23465378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryopreservation of hematopoietic stem/progenitor cells for therapeutic use.
    Watt SM; Austin E; Armitage S
    Methods Mol Biol; 2007; 368():237-59. PubMed ID: 18080475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients.
    Michallet M; Goldet K; Sobh M; Morisset S; Chelghoum Y; Thomas X; Barraco F; Ducastelle S; Labussière H; Renzullo C; Paillet C; Pivot C; Straaten PB; Denis A; Termoz A; Detrait M; Nicolini FE; Jaisson-Hot I
    Cancer; 2013 Jan; 119(1):107-14. PubMed ID: 22744794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
    Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trends in the management of anaemia in solid tumours and haematological malignancies.
    van Eeden R; Rapoport BL
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):189-94. PubMed ID: 27054286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
    Branson K; Chopra R; Kottaridis PD; McQuaker G; Parker A; Schey S; Chakraverty RK; Craddock C; Milligan DW; Pettengell R; Marsh JC; Linch DC; Goldstone AH; Williams CD; Mackinnon S
    J Clin Oncol; 2002 Oct; 20(19):4022-31. PubMed ID: 12351600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.
    Robles NR
    Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.